# GP (HK) invests $12M in CoRISMA for heart failure device rights

China Grand Pharmaceutical and Healthcare Holdings (GP (HK)) will acquire 22.2% equity in CoRISMA MCS Systems for $12 million, and obtain exclusive development, manufacturing and commercialization rights for CoRISMA's heart failure therapeutic system in Greater China and several Southeast Asian countries.

- Type: Partnership
- Announced: 2021-08-06
- Where: United States
- Value: $12.0M
- Status: announced
- Products: advanced heart failure therapeutic system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [China Grand Pharmaceutical and Healthcare](https://endata.com/companies/28136.md)
- [CoRISMA MCS Systems, Inc](https://endata.com/companies/56909.md) (partner)

## Sources

- [grandpharm.com](https://www.grandpharm.com/en/news/gp-hk-enters-into-strategic-cooperation-with-corisma-on-equity-interests-and-products-introducing-a-global-innovative-advanced-heart-failure-therapeutic-system/), 2021-08-06: "The global innovative advanced heart failure therapeutic system introduced by the Group this time is another global innovative product in this field."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.